Advances in the Management. of Breast Cancer
|
|
- Brittany Washington
- 5 years ago
- Views:
Transcription
1 reviews therapy Advances in the Management of Breast Cancer by Rowan T. Chlebowski, MD, PhD, Professor of Medicine, University of California, Los Angeles School of Medicine; Chief, Division of Medical Oncology and Hematology, Harbor-UCLA Medical Center In the United States, an estimated 192,370 women were diagnosed with breast cancer in 2009, accounting for 27% of all new cancer cases. As the second leading cause of cancer deaths in women, an estimated 40,170 deaths were attributable to the disease in The breast cancer death rate has been declining since the 1990s due to screening and early detection and improvement in adjuvant therapy. 2 Etiology, Risk Factors, and Risk Assessment While the etiology of breast cancer is largely unknown, there are identifiable risk factors for developing the disease, including female gender, increasing age, Table 1. Breast Cancer Risk Factors 3 Nonmodifiable Gender (female > male) Increasing age Breast cancer family history Genetic factors (BRCA1 or BRCA2 genes, pten, p53) History of benign breast disease Race/ethnicity Exposure to ionizing radiation Early menarche Late menopause Breast cancer is the most common cancer among women, with one in eight American women at risk for developing invasive disease at some point in their lives. 1 and strong family history (Table 1). A family history of ovarian cancer, a history of breast cancer younger than age 50, and an Ashkenazi Jewish background can identify women more likely to have mutations (BRCA1 or BRCA2) associated with greatly increased breast cancer risk. Several computer models to predict breast cancer risk are in clinical use. Modifiable Use of estrogen plus progestin menopausal hormone therapy Obesity and nonactive lifestyle Alcohol consumption and high-fat diet Nulliparity or first full-term pregnancy at age 30 or older The most commonly used in the United States is the Breast Cancer Risk Assessment Tool, also known as the Gail model. Screening Breast cancer can be detected using several methods for screening, including a clinical breast exam (CBE) and mammography. The most benefit is gained from CBE when used in combination with mammography. Proven to decrease mortality, screening mammography is the mainstay of breast cancer screening and can detect lesions two years prior to discovery by CBE alone. Magnetic resonance imaging (MRI) can be used in conjunction with mammography, but it is recommended only in high-risk patients because it can result in more false-positive findings. 4 14
2 Controversial recommendations made by the U.S. Preventive Services Task Force (USPSTF) in 2009 encourage women at average risk for breast cancer to start biennial mammography screening at age The USPSTF s argument is that screening before age 50 can contribute to unnecessary psychological burden, physical harm, and medical costs. These recommendations are not universally accepted, and the American Cancer Society continues to recommend screening mammography yearly beginning at age 40. Specific populations recognized to be at higher risk are candidates for more intensive screening programs. Pathophysiology Designed for the production and storage of milk, the breast is composed of lobules and ducts surrounded by a stroma composed of fatty and connective tissue, blood vessels, and lymphatic vessels. Most breast cancers are adenocarcinomas and arise from the granular tissue of either the lobules or the ducts. Noninvasive, in situ tumors are localized to the lobules or ducts, while invasive tumors penetrate into the stroma of the breast and can invade lymphatic and vascular structures. Ductal carcinoma in situ (DCIS) is the most common type of noninvasive breast cancer, while lobular carcinoma in situ (LCIS) is considered a risk factor for developing a future malignancy, rather than a true cancer itself. Infiltrating ductal carcinoma is the most common invasive breast cancer, followed in frequency by infiltrating Table 2. Breast Cancer Staging and Survival 6,7 Clinical Description TNM (Tumor, Node, Metastasis) Five-Year Survival Rate Noninvasive Stage 0 DCIS, LCIS 100% Early invasive Locally advanced Metastatic Stage I, II, and some stage IIIA (T0-3, N0-1, M0, and T3N1M0) lobular carcinoma and mixed infiltrating and lobular carcinoma. Several other types of invasive cancer, such as medullary carcinoma, tubular carcinoma, and mucinous carcinoma, are associated with a somewhat better prognosis. Specific signaling pathways that are activated pathologically or via a mutation in the progression of normal breast cell to invasive tumor remain largely unknown. Estrogen signaling and human epidermal growth factor pathway activation are some of the involved processes. Ninety percent of breast cancers are caused by sporadic mutations. 6 The remaining population of patients has mutations caused by a hereditary link, such as the BRCA1/ BRCA2 mutations. Staging and Workup For women presenting with localized disease, characteristics of the tumor play a major role in the risk of recurrence. Three factors include the histologic grade of the tumor, estrogen receptor (ER) and progesterone receptor (PR) status, and human epidermal growth factor receptor 2 (HER2) status. Stage IIIB, IIIC, and some stage IIIA (T0-4, N0-3, M0 but no T3N1M0) Stage IV (any T, any N, M1) % 57% 20% Breast cancer is staged using the American Joint Committee on Cancer TNM (tumor, node, metastasis) system, which takes into account the size and speed of growth of the tumors. After histologic diagnosis, in addition to patient history and physical examination, diagnostic workup can include general laboratory studies (complete blood cell count, liver function tests, platelet count), imaging studies (bilateral mammography, breast ultrasound, MRI), and tumor characteristics (ER, PR, HER2) status. Use of breast MRI for routine staging is controversial. Increasingly, gene pattern expression of tumor samples is being used to provide prognostic and predictive information on potential chemotherapy efficacy. Tests include the 21-gene Oncotype DX and the 70-gene MammaPrint assays. Breast cancer survival is related to stage or extent of disease. Stage 0 refers to noninvasive tumors in the breast. Stages I to IV describe the extent of spread of invasive breast cancers. While five-year relative survival rates are listed in Table 2, note that risk of recurrence and death extends at least 15 years after diagnosis. managedcareoncology.com 15
3 Treatment Options The treatment of breast cancer involves a multimodal approach that may include surgery, radiation, and systemic therapy. Systemic therapies include hormonal therapy, chemotherapy, and biological or targeted therapy. Noninvasive Breast Cancer The goal of treating in situ disease is to prevent either recurrence of in situ disease and/or development of invasive breast cancer. After initial surgical resection, observation alone is often preferred in patients with LCIS because of the low risk of developing invasive cancer (approximately 21% over 15 years). 8 Treatment options available to patients with DCIS include lumpectomy plus radiation, total mastectomy with or without reconstruction, and lumpectomy alone followed by clinical observation. Endocrine therapy with tamoxifen, an estrogen receptor antagonist, can be considered in ER+ or PR+ cases of DCIS. 9 Invasive Breast Cancer Primary surgical management of localized, invasive breast cancer can include lumpectomy plus radiation or mastectomy. Radiation after mastectomy is dependent on the stage of the disease, with women with four or more lymph positive nodes being offered the treatment. Neoadjuvant chemotherapy (chemotherapy prior to surgery) is often employed to shrink large tumors, making the patient eligible for breast-conserving surgery. These neoadjuvant preoperative treatment regimens are similar to the recommended adjuvant therapies that are employed after surgical resection. An area of active investigation is the incorporation of biologic agents, such as vascular endothelial growth factor Table 3. Preferred Adjuvant Chemotherapy Regimens 7 HER2- Disease TAC (docetaxel/doxorubicin/cyclophosphamide) AC T (doxorubicin/cyclophosphamide followed by paclitaxel) TC (docetaxel/cyclophosphamide) HER2+ Disease AC TH (doxorubicin/cyclophosphamide followed by paclitaxel + trastuzumab) TCH (docetaxel, carboplatin, trastuzumab) (VEGF) receptor inhibitor therapy, into the neoadjuvant setting. If the tumor is ER+ or PR+, adjuvant endocrine therapy should be considered. 10,11 Options include tamoxifen, regardless of menopausal status, or aromatase inhibitors (AI), such as anastrozole, letrozole, or exemestane, for postmenopausal women. The optimal agent, sequence of administration, and duration of treatment are under investigation, but use of an AI is especially favored as an initial approach. Depending on risk of recurrence, cytotoxic chemotherapy is often utilized as an adjuvant to surgery. 12 Common adjuvant regimens are included in Table 3. Trastuzumab, a monoclonal antibody that targets the HER2 receptor, should be used in conjunction with chemotherapy in patients who are HER2+. 7 Questions remain regarding optimal adjuvant therapy for patients with HER2+ invasive disease. A phase 3 study awaiting publication, BCIRG-006, compared the disease-free survival (DFS) and overall survival (OS) after treatment of patients with HER2+ resected earlystage disease with an anthracyclinebased regimen (AC T ± H) and a nonanthracycline-containing regimen (TCH). The study resulted in no statistical advantage of DFS favoring the anthracycline regimen; however, the anthracycline arm was associated with more grade 3/4 congestive heart failure and greater loss of left ventricular ejection fraction. The results suggest a nonanthracycline-containing regimen is noninferior and may be an option if cardiotoxicity is an issue. 13 The optimal adjuvant anti-her2 regimen and duration (one year vs. two years) is presently under investigation The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial, which investigates the optimal administration of adjuvant therapy with anti-her2 agents, is ongoing. The study compares the effects of trastuzumab and lapatinib, alone or in combination, on breast cancer recurrence risk and OS. 14 Lapatinib, a small molecule kinase inhibitor targeting both endothelial growth factor receptor and HER2, has previously been approved in combination with capecitabine for patients in the metastatic setting who are refractory to therapy with an anthracycline, a taxane, and a trastuzumab. Metastatic Disease Systemic treatment of metastatic breast cancer (MBC) is intended to prolong survival and enhance quality of life but is not curative. Therefore, for initial recurrence, endocrine treatments are often favored over chemotherapy because they are associated with lower toxicity. 16 Women with ER/PR- tumors or ER/PR+ tumors who are refractory to endocrine therapy are candidates 16
4 Table 4. Preferred Chemotherapy Regimens for Metastatic Breast Cancer 7 Single Agents Combinations Anthracyclines Taxanes doxorubicin, epirubicin, pegylated liposomal doxorubicin paclitaxel,* docetaxel, nab-paclitaxel AC CAF/FAC (cyclophosphamide/doxorubicin/fluorouracil) FEC (fluorouracil/epirubicin/cyclophosphamide) Antimetabolites capecitabine, gemcitabine AT (doxorubicin/docetaxel; doxorubicin/paclitaxel) EC (epirubicin/cyclophosphamide) Other microtubule inhibitors vinorelbine CMF (cyclophosphamide/methotrexate/fluorouracil) GT (gemcitabine/paclitaxel) docetaxel/capecitabine *Preferred agent with bevacizumab for chemotherapy (Table 4). Women with HER2+ tumors benefit from use of anti-her2 therapy (trastuzumab or lapatinib) in their treatment regimens (Table 5). The approach of complete HER2 blockade is also being studied in patients with metastatic HER2+ disease who progress on trastuzumab. Results from a phase 3 trial comparing lapatinib alone to lapatinib plus trastuzumab after progression on trastuzumab indicated an OS benefit of 14.0 vs. 9.5 months for patients being treated with the combination. 19,20 Clinical trials have demonstrated efficacy of other biologic agents in the management of metastatic breast cancer. Bevacizumab, a monoclonal antibody targeting VEGF, has been approved as a first-line agent in combination with paclitaxel for treatment-naïve HER2- patients. The optimal use of bevacizumab in combination with chemotherapy is under investigation (Table 6). (Shortly before press time, a federal health scientist said on July 16 that follow-up studies of Roche s breast cancer drug, bevacizumab, failed to extend the lives of patients, opening the door for it to be withdrawn for use in treating locally recurrent or HER2- metastatic breast cancer in woman who have not previously received chemotherapy.) In addition to new agents targeting extracellular receptors, research in the field of breast cancer is beginning to focus on the complex intracellular signaling pathways. These biologic pathways play a major role in initial cancer development and later in drug resistance (Table 7). The PI3K/Akt/ mtor pathway and poly (ADP-ribose) polymerase (PARP) will be important drug targets in the future. Table 5. Preferred First-Line Agents for HER2+ Metastatic Breast Cancer 7 Trastuzumab-Naïve Patients In combination with trastuzumab: paclitaxel ± carboplatin docetaxel vinorelbine capecitabine Trastuzumab-Exposed Patients lapatinib + capecitabine trastuzumab + other first-line agents trastuzumab + capecitabine trastuzumab + lapatinib (without cytotoxic therapy) Table 6. Results of Key Trials for the Use of Bevacizumab as First-Line Agent in Metastatic Breast Cancer Trial Regimen N Outcome ORR (%) Median PFS (months) Median OS (months) E2100 Paclitaxel vs. paclitaxel + bevacizumab * * AVADO Docetaxel Docetaxel + low-dose bevacizumab Docetaxel + high-dose bevacizumab * * 10.1* RIBBON-1 Capecitabine +/- bevacizumab Taxane +/- bevacizumab Anthracycline +/- bevacizumab vs. 24* 50 vs. 35* 52 vs vs. 5.7* 9.2 vs. 8.0* (pooled analysis) 29 vs vs (pooled analysis) ORR = objective response rate; PFS = progression-free survival; OS = overall survival; *statistically significant managedcareoncology.com 17
5 Table 7. Novel Therapies Under Investigation in Breast Cancer 24 Biologic Target HER Multikinase VEGF PARP PI3K/Akt/mTOR pathway Agent HER3 antibodies HSP90 inhibitors neratinib pertuzumab PI3k inhibitors trastuzumab DM-1 aflibercept axitinib pazopanib sorafenib sunitinib vandetanib ABT-888 AG BSI-201 olaparib PF deforolimus everolimus References 1. National Institutes of Health. Cancer: breast. Surveillance epidemiology and end results (SEER) fact sheet. National Cancer Institute website. Available at: html/breast.html. Accessed March 16, Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin. 2009;59: American Cancer Society. Detailed guide: breast cancer. American Cancer Society website. Available at: factors_for_breast_cancer_5.asp?sitearea=. Accessed March 16, The National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology TM for Breast Cancer Screening and Diagnosis Available at: org/professionals/physician_gls/pdf/breast-screening.pdf. Accessed March 16, U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151: American Cancer Society. Detailed guide: breast cancer. American Cancer Society website. Available at: cancer_5.asp?sitearea=. Accessed March 16, The National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology TM for Breast Cancer Available at: physician_gls/pdf/breast.pdf. Accessed March 16, Haagensen CD, Bodian C, Haagensen DE Jr., eds. Breast Carcinoma: Risk and Detection. Philadelphia, PA: W.B. Saunders; Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 randomised controlled trial. Lancet. 1999;353: Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295: Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1198;351: Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; Slamon D, Eiermann W, Robert N, et al. Phase 3 trial comparing AC-T with AC-TH with TCH in the adjuvant treatment of HER2+ early breast cancer patients: second interim efficacy analysis [abstract]. San Antonio Breast Cancer Symposium Abstract Clinical trials (PDQ). National Cancer Institute website. Available at: hid= Accessed March 17, Tykerb [package insert]. Research Triangle Park, NC: GlaxoSmithKline; Accessed March 17, Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. Oncology. 2008;22: ; discussion 623, Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2+ breast cancer. N Engl J Med. 2005;353: Smith I, Procter M, Gelber RD, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2+ breast cancer: a randomized controlled trial. Lancet. 2007;369: O Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. In: General Session 6 of the 44th Annual ASCO Meeting; 2008 May 30-Jun 3; Chicago, IL. Abstract Blackwell KL, Burnstein HJ, Sledge GW, et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. In: General Session 5 of the 32nd Annual San Antonio Breast Cancer Symposium; 2009 Dec 9-13; San Antonio, TX. Abstract Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: Miles DW, Chan A, Romieu G, et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase 3 AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (MBC) [abstract]. In: General Session 4 of the 32nd Annual San Antonio Breast Cancer Symposium; 2009 Dec 9-13; San Antonio, TX. Abstract Robert N, Dieras V, Glaspy J, et al. Clinical benefit rate and time to response in RIBBON-1, a randomized, double-blind, phase 3 trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of HER2- locally recurrent or metastatic breast cancer (MBC) [abstract]. In: Poster Session 6 of the 32nd Annual San Antonio Breast Cancer Symposium; 2009 Dec 9-13; San Antonio, TX. Abstract Clinical trials (PDQ). National Cancer Institute website. Available at: Accessed March 17,
COME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationBreast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.
Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationBreast Cancer. Breast Cancer. Established breast cancer risk factors. Established breast cancer risk factors. Cancer incidence.
Breast Cancer A buffet of breast cancer topics Wendy Y. Chen, MD MPH Dana-Farber Cancer Institute Brigham and Women s Hospital Disclosures: none Not related to anything presented in this lecture Wendy
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationBeyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer Wednesday, December 11, 2013 7:30 PM 9:30 PM San Antonio,
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationEvolving Practices in Breast Cancer Management
Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationHighlights from the 2009 Annual Meeting of the American Society of Clinical Oncology
BREAST CANCER 24 Breast Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by William J. Gradishar, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationAdvances in Neoadjuvant and Adjuvant Therapy for Breast Cancer
Advances in Neo and Adjuvant Therapy for Breast Cancer Nicole Kounalakis, MD, and Christina Finlayson, MD OVERVIEW Systemic therapy for breast cancer is evolving rapidly. The medical treatment of cancer
More informationLatest News in Breast Cancer Research
Latest News in Breast Cancer Research Highlights from the 2011 San Antonio Breast Cancer Symposium www.cancercare.org This special edition of the CancerCare Connect booklet series highlights cutting-edge
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationPerjeta (pertuzumab)
Perjeta (pertuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201809/16/2018 POLICY A. INDICATIONS The indications
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationBIOLOGICAL THERAPIES FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium
Emerging trends and recommendations BIOLOGICAL THERAPIES FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium Joseph Ragaz, MD, FRCPC Top-line summary Here, Oncology Exchange presents
More informationBreast Cancer Clinical Pathway Committee Development Meeting
Breast Cancer Clinical Pathway Committee Development Meeting Agenda Start Time Topic 8:0 am 8:0 am Welcome, Introductions, and Objectives for the Session 8:0 am 8: am Value-based Care in Breast Cancer
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationGeneral Information Key Points
The content of this booklet was adapted from content originally published by the National Cancer Institute. Male Breast Cancer Treatment (PDQ ) Patient Version. Updated September 29,2017. https://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationBreast Cancer FAQ. How does Breast Cancer spread? Breast cancer spreads by invading into
FAQ Breast Cancer What is Breast Cancer? Breast Cancer is the second leading cause of cancer deaths in women today (second to lung cancer) and is the most common cancer among women excluding non-melanoma
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationBreast Cancer. American Cancer Society
Breast Cancer American Cancer Society Reviewed February 2017 What we ll be talking about How common is breast cancer? What is breast cancer? What causes it? What are the risk factors? Can breast cancer
More informationOne Breast Cancer Annual Report
One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the
More informationJose A Torres, MD 1/12/2017
Jose A Torres, MD 1/12/2017 Background Globally leading cause of cancer related death in women ~249,000 Americans diagnosed with invasive breast cancer ~40,890 will die of their disease Breast cancer risk
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationTrastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment
Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment August 2010 This technology summary is based on information available at the time
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationComing of Age: Breast Cancer in Seniors HYMAN B. MUSS
The Oncologist Understanding and Treating Triple-Negative Breast Cancer Across the Age Spectrum Coming of Age: Breast Cancer in Seniors HYMAN B. MUSS The University of North Carolina Lineberger Cancer
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationBRCA mutation carrier patient: How to manage?
BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationTreatment of HER-2 positive breast cancer
EJC SUPPLEMENTS 6 (2008) 21 25 available at www.sciencedirect.com journal homepage: www.ejconline.com Treatment of HER-2 positive breast cancer Matteo Clavarezza, Marco Venturini * Ospedale Sacro Cuore
More informationHighlights: 2008 San Antonio Breast Cancer Symposium
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/conference-coverage/highlights-2008-san-antonio-breast-cancersymposium/4099/
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationPatient Guide to Breast Cancer Surgery and Treatment. Mercy Cancer Services. baggotstreet.mercy.net/benefits. Your life is our life s work.
Patient Guide to Breast Cancer Surgery and Treatment Your life is our life s work. baggotstreet.mercy.net/benefits Mercy Cancer Services Introduction An estimated one out of eight women will develop breast
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationCase 1. BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care
BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care Leah Karliner, MD MAS University of California San Francisco Primary Care Medicine Update 2009 April 2009 Case 1 AR, a 60 year old African
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationObjectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationBREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
More information